Evidence map›Paper›PMID 24398597›Full record

ReviewClinical pharmacology and therapeutics2014

Prioritizing genomic applications for action by level of evidence: a horizon-scanning method.

W D Dotson, M P Douglas, K Kolor, A C Stewart, M S Bowen, M Gwinn, A Wulf, H M Anders, C Q Chang, M Clyne and 5 more

Abstract readReview
In one paragraph

Review in Clinical pharmacology and therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Which Lynch syndrome screening programs could be implemented in the "real world"? A systematic review of economic evaluations.Genetics in medicine : official journal of the American College of Medical Genetics · 2018
    Pooled it
  2. The Genetic Education for Men (GEM) Trial: Development of Web-Based Education for Untested Men in BRCA1/2-Positive Families.Journal of cancer education : the official journal of the American Association for Cancer Education · 2021
    Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Health equity in the implementation of genomics and precision medicine: A public health imperative.Genetics in medicine : official journal of the American College of Medical Genetics · 2022
    Review
  13. Penetrance and outcomes at 1-year following return of actionable variants identified by genome sequencing.Genetics in medicine : official journal of the American College of Medical Genetics · 2021
    Article
  14. From genes to public health: are we ready for DNA-based population screening?Genetics in medicine : official journal of the American College of Medical Genetics · 2021
    Article
  15. Article
  16. Review
  17. Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2020
    Review
  18. Effective Identification of Lynch Syndrome in Gastroenterology Practice.Current treatment options in gastroenterology · 2019
    Review
  19. Review
  20. Ten years of Genome Medicine.Genome medicine · 2019
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

W D DotsonOffice of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
M P Douglas1] Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA [2] McKing Consulting Corporation, Atlanta, Georgia, USA.
K KolorOffice of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
A C Stewart1] Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA [2] McKing Consulting Corporation, Atlanta, Georgia, USA.
M S BowenOffice of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
M Gwinn1] Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA [2] McKing Consulting Corporation, Atlanta, Georgia, USA.
A Wulf1] Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA [2] Cadence Group, Atlanta, Georgia, USA.
H M Anders1] Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA [2] McKing Consulting Corporation, Atlanta, Georgia, USA.
C Q ChangEpidemiology and Genomics Research Program, National Cancer Institute, Bethesda, Maryland, USA.
M Clyne1] Epidemiology and Genomics Research Program, National Cancer Institute, Bethesda, Maryland, USA [2] Kelly Services, Troy, Michigan, USA.
T K LamEpidemiology and Genomics Research Program, National Cancer Institute, Bethesda, Maryland, USA.
S D SchullyEpidemiology and Genomics Research Program, National Cancer Institute, Bethesda, Maryland, USA.
M MarroneJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
W G FeeroMaine Dartmouth Family Medicine Residency Program, Augusta, Maine, USA.
M J Khoury1] Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA [2] Epidemiology and Genomics Research Program, National Cancer Institute, Bethesda, Maryland, USA.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

As evidence accumulates on the use of genomic tests and other health-related applications of genomic technologies, decision makers may increasingly seek support in identifying which applications have sufficiently robust evidence to suggest they might be considered for action. As an interim working process to provide such support, we developed a horizon-scanning method that assigns genomic applications to tiers defined by availability of synthesized evidence. We illustrate an application of the method to pharmacogenomics tests.

Indexed as

Decision MakingGenomicsGenetic TestingHuman Genome ProjectHumansPharmacogenetics

Identifiers

PMID24398597
PMCPMC4689130

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.